title: Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs.
abstract: BACKGROUND
  A previous retrospective study suggested that a policy of regular anti-pseudomonal antibiotic treatment improved pulmonary function and increased survival in patients with cystic fibrosis chronically infected with Pseudomonas species. The results of a prospective multicentre study to compare the effects on pulmonary function and mortality of three monthly elective anti-pseudomonal antibiotic treatment with conventional symptomatic treatment are reported.
  
  
  METHODS
  Sixty patients with cystic fibrosis, chronically infected with P aeruginosa, were randomised to the two treatment arms (elective or symptomatic) and followed clinically at yearly reviews. The major end points were changes in forced expiratory volume in one second (FEV(1)) and forced vital capacity (FVC). Survival was a secondary end point.
  
  
  RESULTS
  Patients in the symptomatic group received a mean of three antibiotic treatments each year and those in the elective group received four antibiotic treatments during each year of the study. No significant differences in FEV(1) and FVC were found between the two groups after three years. There was a statistically non-significant higher rate of deaths in the elective group (n = 4), three of which were associated with B cepacia infection, compared with the symptomatic group (n = 0).
  
  
  CONCLUSIONS
  This study did not demonstrate an advantage of a policy of elective antibiotic treatment over symptomatic treatment in patients with cystic fibrosis chronically infected with Pseudomonas species.
authors.affiliation: stuart.elborn@bch.n-i.nhs.uk
authors.forename: J S
authors.initials: JS
authors.lastname: Elborn
authors.forename: R J
authors.initials: RJ
authors.lastname: Prescott
authors.forename: B H
authors.initials: BH
authors.lastname: Stack
authors.forename: M C
authors.initials: MC
authors.lastname: Goodchild
authors.forename: J
authors.initials: J
authors.lastname: Bates
authors.forename: C
authors.initials: C
authors.lastname: Pantin
authors.forename: N
authors.initials: N
authors.lastname: Ali
authors.forename: D J
authors.initials: DJ
authors.lastname: Shale
authors.forename: M
authors.initials: M
authors.lastname: Crane
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000150:complications*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D013183:Sputum / Q000382:microbiology; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents